NKTR
Nektar Therapeutics
NASDAQ · USHealthcareBiotechnology
$64.84-5.01%
Price as of Jul 20, 2026
NKTR financials
Nektar Therapeutics financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M |
| Cost of revenue | $0.00 | $30.7M | $36.6M | $21.6M |
| Gross profit | $55.2M | $67.7M | $53.5M | $70.4M |
| Operating expenses | $186.0M | $172.9M | $190.9M | $310.7M |
| Operating income | -$130.8M | -$105.2M | -$137.4M | -$240.2M |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M |
| EBITDA | -$137.0M | -$86.7M | -$243.1M | -$323.9M |
| Basic EPS | $-9.73 | $-8.68 | $-21.79 | $-29.51 |
| Diluted EPS | $-9.73 | $-8.68 | $-21.79 | $-29.51 |
| Balance sheet | ||||
| Cash & equivalents | $15.1M | $44.3M | $35.3M | $88.2M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M |
| Stockholders’ equity | $89.8M | $60.7M | $131.0M | $366.6M |
| Total debt | $148.9M | $102.6M | $117.8M | $131.5M |
| Net debt | $133.8M | $58.3M | $82.5M | $43.3M |
| Cash flow | ||||
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M |
| Capital expenditure | -$171.0K | -$1.5M | -$865.0K | -$5.7M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$3.0M | $0.00 | $0.00 |